Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN67,9367,96-0,73
Msft428,32428,428,45
Nokia4,3854,451,06
IBM239,46239,67-0,89
Mercedes-Benz Group AG52,6252,65-2,73
PFE23,9323,94-1,95
01.05.2025 18:50:51
Indexy online
AD Index online
select
AD Index online
 

  • 01.05.2025 18:50:50
Exelixis (EXEL.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
38,91 -0,61 -0,24 768 056
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 01.05.2025
Popis společnosti
Obecné informace
Název společnostiExelixis Inc
TickerEXEL
Kmenové akcie:Ordinary Shares
RICEXEL.O
ISIN-
Poslední známé roční výsledky03.01.2025
Poslední známé čtvrtletní výsledky03.01.2025
Počet zaměstnanců k 03.01.2025 1 147
Akcie v oběhu k 31.03.2025 275 583 955
MěnaUSD
Konstituent indexůS&P 400 Mid Cap
Kontaktní informace
Ulice1851 Harbor Bay Parkway
MěstoALAMEDA
PSČ94502
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 508 377 000
Fax16508378300

Business Summary: Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Financial Summary: BRIEF: For the fiscal year ended 03 January 2025, Exelixis Inc revenues increased 18% to $2.17B. Net income increased from $207.8M to $521.3M. Revenues reflect CABOMETYX segment increase of 11% to $1.8B, License revenues segment increase of 96% to $349.2M, U.S segment increase of 11% to $1.82B, Europe segment increase from $145M to $318.6M. Net income benefited from Other Research and development decrease of 17% to $695.8M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSMedicinal and Botanical Manufacturing
NAICSIn-Vitro Diagnostic Substance Manufacturing
NAICSBiological Product (except Diagnostic) Manufacturing
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS2007Medicinal & Botanical Mfg
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Medicinal and Botanical Manufacturing
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations
SICCommercial Physical Research
SICMedicinals And Botanicals
SICDiagnostic Substances
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 01.05.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorMichael Morrissey6415.07.2010
Chief Financial Officer, Executive Vice PresidentChristopher Senner5615.07.201515.07.2015
Executive Vice President - Discovery and Translational Research, Chief Scientific OfficerDana Aftab6115.12.202215.12.2022
Executive Vice President, General Counsel, SecretaryJeffrey Hessekiel5510.02.2014
Executive Vice President - CommercialPatrick Haley48
Executive Vice President, Product Development and Medical Affairs and Chief Medical OfficerAmy Peterson57